Blumberg Capital

Thank you Chicago Booth EVC for spending time with us during your trek to Silicon Valley. The group came with great questions, energy, and interest in shaping the next generation of venture capital. Thanks also to The University of Chicago Booth School of Business alumni Steve Gillan, our CFO/COO, for joining the group and sharing advice on maximizing the MBA years for a career in VC (including tips from our more recent MBA grads?Lior Carmel,?Jacob Katz and?Jimmy Z.). We look forward to your next visit to San Francisco!

Our newest Compass newsletter is live! ?? Effective storytelling isn't just about getting attention - it’s about making the right impact with the right people. In the newest Compass, we cover the essentials needed before making a company announcement. For this newsletter, we spoke to startup reporter Christine Hall (prev. Crunchbase News, TechCrunch) for advice on what makes a startup pitch stand out.

We are proud to share that VerAI Discoveries has raised $24M in initial Series B funding led by Insight Partners, with participation from existing investors Blumberg Capital, Chrysalix Venture Capital and Orion Industrial Ventures. This marks our third investment in the company as part of an exciting four year journey?with the VerAI team. The rise of AI and our increasingly electrified and connected world rely on critical minerals.?VerAI's proprietary AI Discovery Platform is engineered to identify concealed deposits of critical minerals with high levels of accuracy. Unlike conventional exploration methods, VerAI's technology detects hidden mineralization beneath covered terrains, reducing risk and cost while increasing the likelihood of discovery. "VerAI has pioneered the use of AI over geological data sets to pinpoint mineral deposits more accurately than any other methods available today, with a sea change in probabilities of discovery.?Not only does this decrease costs to find deposits but it also requires drilling fewer holes, which is a secondary positive impact on the environment." - Stanton Green, VerAI board member and sr. director at Blumberg Capital Congratulations to co-founders Yair Frastai (CEO) and Amitai Axelrod (CTO) and the VerAI team on today's milestone, the journey here and the promising adventure ahead! Thanks to our colleagues Stanton and Jacob Katz for leading us in this adventure with VerAI. More on VerAI's milestone: https://lnkd.in/gmQnJBDt

World Jewish Congress’ Voices of Impact podcast recently connected with David Blumberg for a discussion on his journey from Harvard to venture capital and lessons learned along the way including that "perseverance overcomes a lot of prejudice.” The podcast, hosted by Isaac Raskas Ohrenstein, interviews leaders and changemakers in the Jewish world to explore their impactful work across business, politics, academia, and philanthropy. ?? Listen to the full podcast to learn more about David’s 30+ year journey in venture capital and long-time partnerships with visionary founders from companies such as DoubleVerify, Nutanix, Trulioo, Wunder Mobility, and more. https://lnkd.in/d4BKQihK

Thanks to the supply chain & logistics founders and investors who made our week at Manifest: The Future of Supply Chain & Logistics so productive. Hats off to CNBC’s David Spiegel for moderating a lively investors discussion with our colleague Stanton Green,?Plug and Play Tech Center’s Saeed Amidi and Alexa Liautaud of General Catalyst. ? Our team has invested in supply chain for decades, leading to exits for companies like CaseStack and SupplyPike and long-term partnerships with high-growth companies such as NYSHEX and VerAI Discoveries. If you're a supply chain & logistics founder, please reach out!

Global enterprises rely on Israeli innovation. ?? The recent acquisition of PerfectScale by DoiT highlights the continued demand for Israeli innovation among global enterprises. PerfectScale joins recently acquired Blumberg Capital Israeli portfolio companies such as: ?? SeaLights (acquired by Tricentis) ?? BioCatch (majority acquired by Permira) ?? Finaro (acquired by Shift4) ?? Authomize (acquired by Delinea) ?? Zone7 (acquired by svexa) Blumberg Capital has invested in Israel, its founders and builders for decades and the best is yet to come from the Startup Nation.?We can't wait to share our latest investments in visionary founders based in Israel.

Founder Storiez host, Ephraim Yarmak, sat down with Blumberg Capital managing director, Bruce Taragin, to discuss his journey from lawyer to “billion-dollar VC” and the lessons learned through founders, fellow investors and family. ??

??Tomorrow at #Manifest2025 Join CNBC and supply chain investors for a discussion on the state of supply chain technologies. Blumberg Capital’s Stanton Green, CNBC’s David Spiegel, Plug and Play Tech Center’s Saeed Amidi and General Catalyst’s Alexa Liautaud will explore how innovative solutions are transforming logistics, procurement, and operations, and trends shaping the next generation of resilient, scalable supply chain systems. We’d love to connect with you this week at #Manifest2025!

Startup Project Podcast's?Nataraj Sindam?sat down with?David Blumberg?for a discussion on his evolution as an investor. David shared practical insights on his investment strategy and philosophy, emphasizing the importance of strong teams.? ? David believes human nature is the true north of VC. While tech and market dynamics have transformed dramatically since launching his first fund, one thing remains unchanged: the power of people.? ? From founders with bold ideas like?Oren Netzer?of?DoubleVerify?and DataHeroes,?Dan Sanker?of?SupplyPike?and CaseStack, and?Benny Nachman?of?Jassby, Inc.?and Shift4 Europe (formerly Finaro),?to Blumberg Capital's Innovation Council, it’s about investing in not only companies, but long-term partnerships.? ? ?? Listen to the full episode:?https://lnkd.in/ed7jMDRc

Today, Blumberg Capital portfolio company?Imagene?announced their collaboration with?Tempus AI, a leader in advancing precision medicine and patient care with AI. Imagene’s AI-powered lung assay quickly predicts key non-small cell lung cancer biomarkers from biopsy images. Now combined with Tempus' clinical reach and real-world data, they can achieve important milestones in precision oncology such as: ???Enhancing precision biomarker prediction and personalized care ???Improving AI model performance for lung cancer diagnostics ???Facilitating commercialization This marks a significant step forward in applying advanced AI methodologies to real-world clinical challenges. Thank you to?Dean Bitan?and the Imagene team for your continued commitment to transforming cancer research and diagnostics! We are proud to support your mission.